$8.53
Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Xeris Announces Details for XP-8121 Program Overview Webinar
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain?
Overview
52-week range
$5.25
$10
68% of range
Avg surprise (last 2)
+40.5%
Avg reaction (last 2)
+9.6%
100% positive
Latest IV / EM
184%
EM ±28.7% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.18 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $0.01 | — | — | +116.7% | +4.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | — | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.01 | $-0.03 | +66.7% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.06 | $-0.07 | +14.3% | — | +15.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.09 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.14 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.12 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92M | $83M | — | $74M | $72M | $60M | — | $54M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $5M | $8M | — | $7M | $4M | $-3M | — | $-13M |
| Net income | $-31M | $2M | — | $621,000 | $-2M | $-9M | — | $-16M |
| EPS (diluted) | $-0.18 | $0.01 | — | — | $-0.01 | $-0.06 | — | $-0.11 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $122M | $112M | $111M | $92M | $59M | $58M | $72M | $59M |
| Inventory | $81M | $74M | $69M | $67M | $67M | $53M | $48M | $45M |
| Total current assets | $275M | $252M | $240M | $224M | $186M | $163M | $168M | $163M |
| Total assets | $412M | $392M | $384M | $370M | $335M | $315M | $323M | $321M |
| Long-term debt | $189M | $221M | $220M | $219M | $219M | $218M | $217M | $216M |
| Total liabilities | $422M | $379M | $370M | $371M | $354M | $351M | $353M | $349M |
| Total equity | $-10M | $13M | $14M | $-861,000 | $-19M | $-35M | $-30M | $-28M |